

Pharmaron Beijing (300759 CH)

Landmark CDMO deal to fuel future growth

Pharmaron reported 2025 financial results, with revenue growing by 14.8% YoY to RMB14.10bn, and non-IFRS adj. net profit increasing by 13.0% YoY to RMB1.82bn. Both revenue and profit growth meaningfully accelerated compared to 2024. The Company's 2025 revenue and adj. net profit came in 0.5% and 0.7% higher than our estimates, respectively, aligning with our expectations. Looking ahead, mgmt. expects revenue to grow by 12-18% YoY in 2026. It is worth noting that this guidance incorporates a negative impact of 3ppts from FX.

■ **Global customer demand continued to expand.** Driven by the penetration of strategic clients within the lab services and deliveries of CDMO projects, revenue from global Top20 pharma clients surged by 29.4% YoY, far exceeding the Company's overall growth. Similarly, revenue from European clients grew by 27.4% YoY, also well above the Company's average, primarily driven by effective go-to-market strategies and steady advancement of CDMO pipeline. Newly signed orders increased by over 14% YoY, extending the robust growth trend following a >20% YoY increase in 2024. As the core business, lab services saw its new bookings grow by ~12% YoY in 2025. Meanwhile, small molecule CDMO also showed encouraging momentum, delivering ~13% YoY growth in new orders. During the year, the segment added 24 PhIII and 15 PPQ & commercialization projects, continuously elevating its commercial manufacturing potential going forward. Furthermore, the growth of new orders in clinical development segment outpaced the Company's average, indicating a stabilization and early recovery in clinical demand from domestic clients and the Company's expanding market share.

■ **Pivotal breakthroughs in small molecule CDMO commercial services.** In Mar 2026, Pharmaron announced a commercial DP agreement with Eli Lilly for the oral GLP-1 drug, Orforglipron, a potential blockbuster. Under this agreement, Eli Lilly will invest US\$200mn in Pharmaron to support the build-out of technical capabilities, with the potential to further expand collaboration scope. The milestone partnership will not only generate significant incremental revenue in the future (despite limited contribution for 2026), but also signifies that Pharmaron's CDMO platform fully complies with the stringent quality systems of top-tier pharma companies. Consequently, this will serve as a powerful endorsement for Pharmaron to continuously expand in global market. Beyond the breakthrough in DP services, Pharmaron's CDMO business has also established its commercial API capabilities. Its API facilities in Shaoxing and Ningbo have both passed the FDA inspections, while its first innovative API project in the US was approved in 4Q25. Given the DP partnership with Eli Lilly and other pipeline advancements, we expect the small molecule CDMO business to grow at a faster pace than the Company's other business lines over the next three years.

■ **Maintain BUY.** We raise our DCF-based TP from RMB38.08 to RMB39.00 (WACC of 9.32%; terminal growth of 2.0%), to reflect a more positive trend of global demand on R&D and manufacturing outsourcing. We forecast Pharmaron's revenue to grow by 16.4%/ 15.9%/ 14.9% YoY and adj. net profit to increase by 18.7%/ 17.7%/ 16.5% YoY in 2026E/ 27E/ 28E, respectively.

Earnings Summary

(YE 31 Dec)	FY24A	FY25A	FY26E	FY27E	FY28E
Revenue (RMB mn)	12,276	14,095	16,410	19,019	21,855
YoY growth (%)	6.4	14.8	16.4	15.9	14.9
Adjusted net profit (RMB m)	1,607	1,816	2,156	2,537	2,955
YoY growth (%)	(15.6)	13.0	18.7	17.7	16.5
EPS (Adjusted) (RMB)	0.91	1.03	1.17	1.38	1.61
Consensus EPS (RMB)	na	na	1.19	1.45	1.78
P/E (Adjusted) (x)	30.8	27.1	23.8	20.3	17.4

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price	RMB39.00
(Previous TP)	RMB38.08)
Up/Downside	39.4%
Current Price	RMB27.98

China Healthcare

Benchen HUANG, CFA

huangbenchen@cmbi.com.hk

Jill WU, CFA

(852) 3900 0842

jillwu@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	51,407.2
Avg 3 mths t/o (RMB mn)	678.9
52w High/Low (RMB)	35.90/22.06
Total Issued Shares (mn)	1837.3

Source: FactSet

Shareholding Structure

HK investors	20.0%
De Facto Controllers	18.2%


Source: HKEX

Share Performance

	Absolute	Relative
1-mth	-5.5%	1.6%
3-mth	-1.6%	1.8%
6-mth	-21.7%	-15.2%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Earnings revision

RMB mn	New			Old			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	16,410	19,019	21,855	16,092	18,710	na	1.98%	1.65%	na
Gross profit	5,871	6,964	8,199	5,550	6,590	na	5.78%	5.67%	na
Operating profit	2,439	2,853	3,311	2,424	2,843	na	0.65%	0.36%	na
Non-IFRS net profit	2,156	2,537	2,955	2,126	2,523	na	1.38%	0.53%	na
Non-IFRS EPS (RMB)	1.17	1.38	1.61	1.16	1.37	na	1.34%	0.49%	na
Gross margin	35.78%	36.62%	37.52%	34.49%	35.22%	na	+1.29ppt	+1.39ppt	na
Operating margin	14.86%	15.00%	15.15%	15.06%	15.19%	na	-0.20ppt	-0.19ppt	na
Net margin	13.14%	13.34%	13.52%	13.21%	13.49%	na	-0.08ppt	-0.15ppt	na

Source: Company data, CMBIGM estimates

Figure 2: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	16,410	19,019	21,855	16,152	18,605	22,019	1.60%	2.23%	-0.75%
Gross profit	5,871	6,964	8,199	5,746	6,774	8,135	2.18%	2.81%	0.79%
Operating profit	2,439	2,853	3,311	2,553	3,103	4,034	-4.46%	-8.06%	-17.91%
Non-IFRS net profit	2,156	2,537	2,955	2,107	2,567	3,181	2.30%	-1.19%	-7.09%
Non-IFRS EPS (RMB)	1.17	1.38	1.61	1.19	1.45	1.78	-1.41%	-5.05%	-9.48%
Gross margin	35.78%	36.62%	37.52%	35.58%	36.41%	36.95%	+0.20ppt	+0.21ppt	+0.57ppt
Operating margin	14.86%	15.00%	15.15%	15.81%	16.68%	18.32%	-0.94ppt	-1.68ppt	-3.17ppt
Net margin	13.14%	13.34%	13.52%	13.04%	13.80%	14.45%	+0.09ppt	-0.46ppt	-0.92ppt

Source: Bloomberg, CMBIGM estimates

Figure 3: Risk-adjusted DCF valuation

DCF Valuation (in Rmb mn)	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	2,739	3,153	3,611	4,352	5,179	6,085	7,058	8,082	9,132	10,183
Tax rate	18.00%	18.00%	18.00%	18.00%	18.00%	18.00%	18.00%	18.00%	18.00%	18.00%
EBIT*(1-tax rate)	2,246	2,585	2,961	3,568	4,246	4,990	5,788	6,627	7,489	8,350
+ D&A	1,278	1,400	1,486	1,761	2,060	2,380	2,713	3,052	3,388	3,709
- Change in working capital	-200	-475	-516	-611	-715	-826	-942	-1,060	-1,176	-1,288
- Capex	-2,500	-2,000	-2,000	-2,000	-2,000	-2,000	-2,000	-2,000	-2,000	-2,000
FCFF	823	1,510	1,931	2,718	3,591	4,543	5,559	6,619	7,700	8,771
Terminal value										122,306
Terminal growth rate										2.00%
WACC										9.32%
Cost of Equity										12.50%
Cost of Debt										4.00%
Equity Beta										1.05
Risk Free Rate										2.00%
Market Risk Premium										10.00%
Target Debt to Asset ratio										35.00%
Effective Corporate Tax Rate										15.00%
PV of terminal value (RMB mn)										50,194
Total PV (RMB mn)										73,836
Net debt (RMB mn)										1,621
Minority interest (RMBmn)										566
Equity value (RMB mn)										71,649
# of shares (mn)										1,837
Price per share (RMB per share)										39.00

Source: CMBIGM estimates

Figure 4: Sensitivity analysis of DCF model

		WACC				
		8.32%	8.82%	9.32%	9.82%	10.32%
Terminal growth rate	4.00%	64.26	56.38	50.01	44.77	40.38
	3.50%	58.66	52.02	46.55	41.97	38.09
	2.00%	47.18	42.78	39.00	35.73	32.87
	2.50%	50.35	45.37	41.15	37.52	34.39
	2.00%	47.18	42.78	39.00	35.73	32.87

Source: CMBIGM estimates

Financial Summary

INCOME STATEMENT	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Revenue	11,538	12,276	14,095	16,410	19,019	21,855
Cost of goods sold	(7,414)	(8,073)	(9,185)	(10,539)	(12,055)	(13,656)
Gross profit	4,124	4,203	4,910	5,871	6,964	8,199
Operating expenses	(2,390)	(2,422)	(2,765)	(3,432)	(4,111)	(4,888)
Selling expense	(253)	(258)	(306)	(406)	(509)	(628)
Admin expense	(1,607)	(1,585)	(1,736)	(2,104)	(2,495)	(2,922)
R&D expense	(448)	(469)	(576)	(720)	(853)	(1,024)
Others	(83)	(110)	(146)	(203)	(254)	(314)
Operating profit	1,734	1,781	2,145	2,439	2,853	3,311
Gain/loss on financial assets at FVTPL	19	2	66	100	100	100
Investment gain/loss	45	542	(102)	100	100	100
Net interest income/(expense)	(5)	(143)	(156)	(94)	(74)	(56)
Other income/expense	45	(90)	(40)	100	100	100
Pre-tax profit	1,838	2,091	1,913	2,646	3,079	3,556
Income tax	(256)	(377)	(358)	(476)	(554)	(640)
After tax profit	1,582	1,714	1,555	2,169	2,525	2,916
Minority interest	19	79	109	108	126	146
Net profit	1,601	1,793	1,664	2,278	2,651	3,061
Adjusted net profit	1,903	1,607	1,816	2,156	2,537	2,955
Gross dividends	357	354	366	456	530	612
BALANCE SHEET						
YE 31 Dec (RMB mn)						
Current assets	10,874	7,608	7,778	9,336	10,745	12,560
Cash & equivalents	5,919	1,690	1,017	2,295	3,015	4,088
Account receivables	2,242	2,414	2,722	2,990	3,465	3,981
Inventories	1,013	1,117	1,472	1,485	1,699	1,924
Financial assets at FVTPL	622	1,120	714	714	714	714
Other current assets	684	810	1,387	1,387	1,387	1,387
Contract assets	394	458	466	466	466	466
Non-current assets	15,602	16,319	19,316	21,238	22,538	23,752
PP&E	6,497	7,809	8,933	10,463	11,371	12,193
Right-of-use assets	776	560	499	342	186	29
Deferred income tax	153	193	263	263	263	263
Intangibles	789	791	1,197	1,134	1,072	1,009
Goodwill	2,781	2,761	3,586	3,586	3,586	3,586
Long-term investments	723	649	640	640	640	640
Other non-current assets	3,884	3,557	4,199	4,810	5,421	6,033
Total assets	26,477	23,927	27,094	30,574	33,283	36,313
Current liabilities	3,654	4,224	8,364	8,944	9,658	10,384
Short-term borrowings	577	765	1,265	1,765	2,265	2,765
Account payables	412	477	607	687	901	1,127
Tax payable	238	219	207	207	207	207
Other current liabilities	1,686	1,928	5,324	5,324	5,324	5,324
Contract liabilities	741	835	961	961	961	961
Non-current liabilities	9,584	5,481	2,991	2,991	2,991	2,991
Long-term borrowings	4,308	4,377	1,772	1,772	1,772	1,772
Bond payables	3,892	0	0	0	0	0
Obligations under finance leases	585	401	379	379	379	379
Other non-current liabilities	799	702	840	840	840	840
Total liabilities	13,239	9,705	11,355	11,935	12,650	13,376
Share capital	1,787	1,778	1,779	2,966	2,966	2,966
Capital surplus	5,222	5,008	4,950	4,950	4,950	4,950
Retained earnings	5,205	6,443	7,679	9,501	11,622	14,071
Other reserves	343	390	656	656	656	656
Total shareholders equity	12,557	13,619	15,064	18,073	20,194	22,643
Minority interest	681	604	674	566	440	294
Total equity and liabilities	26,477	23,927	27,094	30,574	33,283	36,313

CASH FLOW	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	1,838	2,091	1,913	2,646	3,079	3,556
Depreciation & amortization	1,009	1,145	1,270	1,278	1,400	1,486
Tax paid	(256)	(377)	(358)	(476)	(554)	(640)
Change in working capital	64	(117)	(10)	(200)	(475)	(516)
Others	100	(166)	406	(106)	(126)	(144)
Net cash from operations	2,754	2,577	3,221	3,140	3,324	3,741
Investing						
Capital expenditure	(2,865)	(2,041)	(2,669)	(2,500)	(2,000)	(2,000)
Acquisition of subsidiaries/ investments	(2,113)	(3,197)	(5,120)	(3,000)	(3,000)	(3,000)
Net proceeds from disposal of short-term investments	2,720	3,227	3,409	2,500	2,500	2,500
Others	7	(13)	6	0	0	0
Net cash from investing	(2,251)	(2,024)	(4,374)	(3,000)	(2,500)	(2,500)
Financing						
Dividend paid	(458)	(548)	(531)	(549)	(604)	(668)
Net borrowings	3,612	(3,771)	1,096	500	500	500
Proceeds from share issues	971	11	17	1,187	0	0
Others	(209)	(488)	(204)	0	0	0
Net cash from financing	3,915	(4,797)	377	1,138	(104)	(168)
Net change in cash						
Cash at the beginning of the year	1,360	5,789	1,623	1,017	2,295	3,015
Exchange difference	11	78	(4)	0	0	0
Cash at the end of the year	5,789	1,623	843	2,295	3,015	4,088
GROWTH	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Revenue	12.4%	6.4%	14.8%	16.4%	15.9%	14.9%
Gross profit	9.4%	1.9%	16.8%	19.6%	18.6%	17.7%
Operating profit	2.5%	2.7%	20.4%	13.7%	17.0%	16.1%
Net profit	16.5%	12.0%	(7.2%)	36.9%	16.4%	15.5%
Adj. net profit	3.8%	(15.6%)	13.0%	18.7%	17.7%	16.5%
PROFITABILITY	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Gross profit margin	35.7%	34.2%	34.8%	35.8%	36.6%	37.5%
Operating margin	15.0%	14.5%	15.2%	14.9%	15.0%	15.2%
Adj. net profit margin	16.5%	13.1%	12.9%	13.1%	13.3%	13.5%
Return on equity (ROE)	13.9%	13.7%	11.6%	13.7%	13.9%	14.3%
GEARING/LIQUIDITY/ACTIVITIES	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Net debt to equity (x)	0.2	0.3	0.1	0.1	0.1	0.0
Current ratio (x)	3.0	1.8	0.9	1.0	1.1	1.2
Receivable turnover days	65.2	69.2	66.5	66.5	66.5	66.5
Inventory turnover days	50.6	48.1	51.4	51.4	51.4	51.4
Payable turnover days	58.0	50.4	51.6	51.6	51.6	51.6
VALUATION	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
P/E (adjusted)	26.1	30.8	27.1	23.8	20.3	17.4
P/B	3.7	3.5	3.1	2.8	2.5	2.2
P/CFPS	18.0	19.2	15.3	16.4	15.5	13.7
Div yield (%)	0.7	0.7	0.7	0.9	1.0	1.2

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.